Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund
Deal Size: $12.2 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 21, 2020
The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.